文献速递肿瘤 PET/CT放射性药物与辐射防护

评估[18F]AlF-NYM005的安全性、生物分布与剂量学及在透明细胞肾细胞癌中的初步经验:一项前瞻性试验的中期分析

Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-12-16

这项首次人体试验前瞻性纳入35例疑似原发性肾恶性肿瘤或有透明细胞肾细胞癌病史的患者,评估新型碳酸酐酶IX靶向小分子[18F]AlF-NYM005的安全性、生物分布与剂量学,并进行PET/CT诊断效能分析。结果显示示踪剂合成放射化学纯度>95%,平均标记产率36.5±8.3%,所有患者耐受良好,未见不良反应,全身有效剂量为7.6E-03 mSv/MBq。初步诊断研究显示[18F]AlF-NYM005 PET/CT在诊断原发性或转移性透明细胞肾细胞癌方面结果令人期待。

要点

  • 35例患者前瞻性纳入,[18F]AlF-NYM005 PET/CT耐受良好,未见不良反应。
  • 全身有效剂量为7.6E-03 mSv/MBq,肾脏、胃和肝脏摄取最高。
  • 所有病灶在注射后30分钟内可检出,患者水平灵敏度93.8%/92.3%(组1/组2)。

核心结论

  • 这项在透明细胞肾细胞癌患者中开展的先导研究证明[18F]AlF-NYM005安全、辐射剂量学可接受、生物分布良好且肿瘤摄取优异。
  • 初步诊断研究表明[18F]AlF-NYM005 PET/CT具有潜在应用价值,在诊断原发性或转移性透明细胞肾细胞癌方面显示出令人期待的结果。

研究设计与样本

  • 首次人体研究,前瞻性招募35例疑似原发性肾恶性肿瘤或有透明细胞肾细胞癌病史的患者。
  • [18F]AlF-NYM005采用全自动卡盒模块Mortenon M1(诺宇,中国)合成。
  • 所有患者接受[18F]AlF-NYM005 PET/CT检查并测量SUVmax,其中5例接受下腹部动态PET/CT扫描(120分钟)。
  • 另5例透明细胞肾细胞癌患者在注射后30、60、90和120分钟接受全身PET扫描(其中1例额外接受150和180分钟扫描)以评估生物分布与剂量学。
  • 动态数据采用Patlak模型计算流入常数Ki,全身生物分布以时间-放射性曲线描述主要器官动态摄取模式。

主要发现

  • [18F]AlF-NYM005合成放射化学纯度>95%,平均标记产率36.5±8.3%。
  • 所有患者耐受PET检查良好,未见不良反应。
  • 全身有效剂量为7.6E-03 mSv/MBq,肾脏、胃和肝脏摄取最高,贡献有效剂量0.0126±0.0029 mSv/MBq。
  • 时间-放射性曲线显示注射后2小时肿瘤高摄取且滞留时间长,血液池、肾脏、肝脏和肿瘤病灶中示踪剂快速升高后快速下降,表明其经血液和尿液快速清除。
  • 原发性肾脏病灶Ki均值为0.082±0.057 ml/g/min,CAIX阳性肿瘤快速摄取,所有病灶在30分钟内可检出,后续多时间点扫描未发现额外病灶。

关键数值与推荐

  • 患者水平灵敏度、特异度和准确率:组1为93.8%、75.0%和90%,组2为92.3%、100%和93.3%。
  • 淋巴结分析:灵敏度92.9%、特异度90.5%、准确率91.8%。
  • 远处转移分析:灵敏度90.5%、特异度91.3%、准确率90.6%。
  • 原发性透明细胞肾细胞癌病灶[18F]AlF-NYM005 PET/CT的SUVmax为15.5±7.35。
  • 肿瘤摄取与免疫组化染色结果呈正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文标题与摘要写明为中期分析(interim analysis)及先导研究(pilot study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This first-in-human study aimed to evaluate the radiation dosimetry and whole-body biodistribution of [18F]AlF-NYM005, a novel small-molecule carbonic anhydrase IX (CAIX) targeting agent, and to investigate its ability to detect CAIX-positive tumors using PET scans in a cohort of clear cell renal cell carcinoma (ccRCC) patients. METHODS: [18F]AlF-NYM005 was synthesized using a fully automatic cassette module Mortenon M1 (Nuoyu, China). Thirty-five patients with a suspicious lesion considered primary renal malignancy or a history of ccRCC were prospectively recruited and studied. All patients underwent [18F]AlF-NYM005 PET/CT examinations and the maximum standardized uptake value (SUVmax) was measured on conventional [18F]AlF-NYM005 PET/CT images. Among these patients, five patients underwent dynamic [18F]AlF-NYM005 PET/CT scanning (120 min) of the lower abdomen. Another subset of five ccRCC patients underwent sequential whole-body PET scans at 30, 60, 90, and 120 min (one of the five patients underwent additional 150 min and 180 min scans) after [18F]AlF-NYM005 injection to assess biodistribution and dosimetry. The influx constant (Ki) was calculated from the dynamic [18F]AlF-NYM005 PET/CT data using the Patlak model. Whole-body biodistribution was calculated as time-activity curves (TACs) describing dynamic uptake patterns in the patients' major organs, followed by calculation of tracer kinetics and cumulative organ activity. Effective doses of [18F]AlF-NYM005 and individual organ doses were also calculated. RESULTS: [18F]AlF-NYM005 was successfully synthesized with a radiochemical purity of > 95% and an average labeling yield of 36.5 ± 8.3%. All patients tolerated the PET examinations well, and no adverse side effects were observed. The total body effective dose was 7.6E-03 mSv/MBq. The highest agent uptake was observed in the kidneys, stomach, and liver, contributing to an effective dose of 0.0126 ± 0.0029 mSv/MBq. The TACs showed optimal normal organ uptake with high tumor uptake and long retention of up to 2 h post-injection. Notably, a rapid increase of the tracer followed by a rapid decrease in the blood pool, kidney, liver, and tumor lesions was observed, indicating that [18F]AlF-NYM005 was rapidly eliminated from blood and urine. For the kinetic data analysis, the Ki for the primary kidney lesions had a mean of 0.082 ± 0.057 ml/g/min. The CAIX-positive tumors displayed rapid uptake, and all lesions were detectable within 30 min, with no additional lesions observed in the subsequent multi-time point scans. The patient-level sensitivity, specificity, and accuracy of [18F]AlF-NYM005 PET/CT were 93.8%, 75.0%, and 90% for group 1 and 92.3%, 100%, and 93.3% for group 2, respectively. For per-lymph node analysis, [18F]AlF-NYM005 PET/CT demonstrated 92.9% sensitivity, 90.5% specificity, and 91.8% accuracy in diagnosing metastatic lymph nodes. For per-distant metastasis analysis, it showed 90.5% sensitivity, 91.3% specificity, and 90.6% accuracy. The SUVmax of [18F]AlF-NYM005 PET/CT for primary ccRCC lesions was 15.5 ± 7.35. Tumor uptake was positive correlated with immunohistochemical staining findings. CONCLUSION: This pilot study in ccRCC patients has demonstrated the safety, acceptable radiation dosimetry, favorable biodistribution, and exceptional tumor uptake of [18F]AlF-NYM005. The preliminary diagnostic study indicated the potential utility of [18F]AlF-NYM005 PET/CT, showing promising results in the diagnosis of primary or metastatic ccRCC. TRIAL REGISTRATION: This study was registered at ClinicalTrial.gov (ChiCTR2200058108) as NYPILOT on 29 March, 2022.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yang L, Guo W, Ding H, et al. Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial. Eur J Nucl Med Mol Imaging. 2024. PMID: 39676103. doi:10.1007/s00259-024-07007-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。